Abstract
Objective To provide data for the monitoring of adverse drug reactions (ADR) induced by new anti-tumor drugs and for early warning of danger signals and pharmaceutical monitoring of ADR. Methods Ninety-one reports of ADR of new anti-tumor drugs submitted to the National Adverse Drug Reaction Monitoring Center by Jiyuan People’s Hospital between 2018 and 2022 were retrospectively analyzed according to the patients’ age, gender, BMI, primary diseases, systems-organs involved, usage of drugs and outcomes. Results ADR of new anti-tumor drugs mainly affected the skin and its accessory systems in 32 cases (35.16%), and the digestive system in 20 cases (21.98%), with diarrhea (25.00%)as the most common type of ADR in the digestive system. Multiple logistic regression analysis showed that the independent risk factors for ADR of the digestive system were lower BMI and concomitant medication. Patients with ADR of the digestive system related to immune checkpoint inhibitors took a longer time to recover (2 weeks to 1 month). Conclusion Clinical pharmacists are to be alert to ADR of new anti-tumor drugs among patients under concomitant medication or with lower BMI and manage adverse reactions caused by immune checkpoint inhibitors.
| Translated title of the contribution | Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital |
|---|---|
| Original language | Chinese (Traditional) |
| Pages (from-to) | 1273-1278 |
| Number of pages | 6 |
| Journal | Chinese Journal of Pharmacovigilance |
| Volume | 20 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 15 2023 |
Keywords
- adverse drug reactions
- concomitant medication
- digestive system
- immune checkpoint inhibitors
- new anti-tumor drugs
- pharmaceutical care
- risk factors
Fingerprint
Dive into the research topics of 'Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver